Online ISSN: 2515-8260

Keywords : Osteosarcoma


Deepak Kumar, Priyanka Sharma, Nilam Bhasker, Shivanjali Raghuvanshi, Rajeshwar Nath Srivastava, Dharmendra Kumar

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 4, Pages 2212-2219

Introduction: Osteosarcoma (OS) is the relatively most prevalent bone malignancy accounting for 20% of primary bone tumors. Differential diagnosis of OS is a daunting problem as they can masquerade with different kinds of bone tumors. None of the studies correlate the radiological findings of suspected cases of osteosarcoma with biopsy.
Purpose: The purpose of this retrospective study is to correlate the radiological findings with biopsy of suspected osteosarcoma.
Materials and Methods: The current retrospective study was carried out in the Department of Orthopaedics in collaboration of Department of Pathology at a tertiary care center in north India from 2015 to 2021. A total of 162 patients of suspected OS included in this study after carefully examination of clinical and radiological features analyzed by two Orthopaedic surgeons. The differential diagnosis of OS was observed in all patients through analyzing the clinical and radiological features followed by biopsy. The accuracy of radiology was calculated against biopsy procedure. 
Results: Out of 162 patients, 102 patients were male and 60 were female with a mean age of 29.65±10.55 years. The accuracy of clinical and radiological findings as compared to biopsy diagnostic procedures was 44.44%. A discrepancy between radiology and biopsy was 55.56%.
Conclusion: Radiological finding reveals that OS mimics different kinds of tumors reflected with low diagnostic accuracy of radiology. Hence, biopsy must consider confirming the diagnosis of bone tumors.          

Design, Synthesis, Biological And In Silico Evaluation Of Phenylene (Bis) Hydrazone Derivatives Against Osteosarcoma Cancer

Pilli Govindaiah; Rakesh Kumar; Praveen Kumar Guttula; Mukesh Kumar Gupta; Jaya Prakash M

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 2617-2632

Three sets of differentphenylene-bis(hydrazone) derivatives namely,Gc, Gd and Ge,were designed, synthesized and evaluated for their molecular properties andin vitro anticancer activity against human osteosarcoma MG-63 cells. All compounds showed potent anticancer activity against the MG63 cells with IC50ranging from 18.27 to 21.68μM. Among three sets of compounds,Ge showed the most potent anticancer activity against osteosarcoma MG63 cells and was superior to standard anticancer reference drug,methotrexate (MTX). All compounds were characterized by spectroscopic studies (FT-IR, 1H NMR, and13C NMR). In silicomolecular properties and drug-like properties were predicted by using Osiris property explorer software. None of Gc and Ge set of compounds violated Lipinski’s boundaries thereby suggesting good oral bioavailability. All the synthesized compounds possessed good pharmacokinetic properties in terms of absorption, distribution, metabolism and toxicity (ADMET). However, the GdSeries compoundswere predicted to be capableof crossing BBB due to their high lipophilicity. The Gc and Ge series of compounds showed good pharmacokinetic parameters within the acceptable range. All the synthesized drugs were predicted to have better pharmacokinetic properties thanthe MTX reference drug.Taken together, our study suggests that Ge series derivatives may be considered as lead drug molecules for possible anticancer applications to be useful against osteosarcoma.